GleamWall
中文EN

INKT MiNK Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1840229 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY10.8%
TTM EPS YoY25.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-95.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets297.2%
Debt / equity—
Current ratio0.97x
Interest coverage317.82x

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-33.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$5.76M$6.34M
SG&A expense$6.73M$4.31M
Operating income-$12.64M-$11.29M
Interest expense-$110,000-$93,000
Net income-$12.49M-$10.78M
EBITDA-$12.46M-$11.07M
EPS (basic)-2.93-2.86
EPS (diluted)-2.93-2.86
Weighted avg. shares (diluted)4.27M3.77M
Banking
Net interest income$180,246$172,568
Balance sheet
Cash & equivalents$13.36M$4.58M
Current assets$13.85M$4.99M
PP&E, net$390,869$732,929
Total assets$14.24M$5.72M
Current liabilities$13.03M$6.96M
Total liabilities$28.47M$25.31M
Shareholders' equity-$14.23M-$19.59M
Shares outstanding4.71M3.96M
Cash flow statement
Operating cash flow-$5.93M-$9.56M
Financing cash flow$14.72M$10.82M
Depreciation & amortization$181,745$215,437
Stock-based compensation$2.67M$1.81M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.